Wednesday, July 8, 2026

pharma · Acne Vulgaris · Pruritus · VYNE

VYNE Therapeutics

VYNE Therapeutics clinical programs — 30 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
Status
Public
HQ
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Founded
2003
Employees
47
Programs
30
Drugs
16
Patents
7
Intelligence · Clinical Programs

VYNE Therapeutics projects

30 ClinicalTrials.gov programs sponsored by VYNE Therapeutics.

VYNE Therapeutics has 30 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule terminated

    3 trials
  2. 5mg Serlopitant Tablets

    VYNE Therapeutics

    Pruritus

    phase 3 small molecule completed

    2 trials
  3. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials
  4. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial
  5. FMX103 1.5%

    VYNE Therapeutics

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial
  6. FMX103 minocycline foam 1.5%

    VYNE Therapeutics

    Facial Papulopustular Rosacea

    phase 3 small molecule completed

    2 trials
  7. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial
  8. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial
  9. Comparator: MK0594 5 mg/day

    VYNE Therapeutics

    Alcohol Dependence

    phase 2 small molecule terminated

    1 trial
  10. FCD105

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 other completed

    1 trial
  11. FDX104 (4% Doxycycline)

    VYNE Therapeutics

    Rash Due to Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule completed

    1 trial
  12. FMX-103 1.5%

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule completed

    1 trial
  13. FMX114

    VYNE Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial
  14. MK0594

    VYNE Therapeutics

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial
  15. Permethrin Foam 4%

    VYNE Therapeutics

    Scabies

    phase 2 small molecule completed

    1 trial
  16. Serlopitant

    VYNE Therapeutics

    Pruritus

    phase 2 small molecule terminated

    1 trial
  17. Serlopitant High Dose

    VYNE Therapeutics

    Pruritus

    phase 2 small molecule completed

    1 trial
  18. Serlopitant Tablet

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial
  19. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Impetigo

    phase 2 small molecule completed

    1 trial
  20. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule terminated

    1 trial
  21. Topical Minocycline Foam FXFM244

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial
  22. VPD-737

    VYNE Therapeutics

    Chronic Pruritus

    phase 2 small molecule completed

    1 trial
  23. VPD-737

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial
  24. VYN201 Gel

    VYNE Therapeutics

    Non-segmental Vitiligo

    phase 2 small molecule terminated

    1 trial
  25. serlopitant

    VYNE Therapeutics

    Prurigo Nodularis

    phase 2 small molecule completed

    1 trial
  26. FMX-101

    VYNE Therapeutics

    Healthy

    phase 1 small molecule completed

    3 trials
  27. FMX101

    VYNE Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial
  28. FMX101 vehicle

    VYNE Therapeutics

    Acne Vulgaris

    phase 1 small molecule completed

    1 trial
  29. FMX101, Minocycline 4% foam

    VYNE Therapeutics

    Acne

    phase 1 small molecule completed

    1 trial
  30. Isotretinoin

    VYNE Therapeutics

    Acne Vulgaris

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does VYNE Therapeutics have?

30 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.